>Voeg code toe voor de </head> tag.trademark

Asian characters : good fit for trademarks in the EU? (Novagraaf)

Author: Anca Draganescu-Pinawin (Novagraaf) Date of publication: 15/01/2018 How is a trademark, containing or composed solely of Asian characters, assessed in the EU? This question is especially of interest to Asia-based businesses seeking to bring their brands to the EU market, while retaining the corporate identity that they have developed in their

2018-01-17T12:21:57+00:00 17 januari 2018|Categories: Intellectuele rechten Privacy, IT & IP recht|Tags: , |

Combination of descriptive terms eligible for trademark protection (Novagraaf)

Author: Frouke Hekker (Novagraaf) Date of publication: 31/10/2017 Trademark applications frequently fail due to lack of distinctiveness. However, it is possible to overcome this barrier to registration for marks combining descriptive and/or non-distinctive elements, if the sign as a whole creates an overall distinctive impression, as Novagraaf’s Frouke Hekker explains.

2017-11-02T14:32:41+00:00 2 november 2017|Categories: Intellectuele rechten Privacy, IT & IP recht|Tags: , , |

‘BREXIT’ passes EU trademark test (Novagraaf)

Author: Myrthe Pardoen (Novagraaf) Date of publication: 13/10/2017 As we have written previously, the European Commission published a position paper on IP rights after Brexit in September, setting out its ideas on how it wants to see unitary IP rights handled after Great Britain departs from the EU. But, this wasn’t the only

2017-10-23T08:27:21+00:00 23 oktober 2017|Categories: Intellectuele rechten Privacy, IT & IP recht|Tags: , , |

Yondelis v Yloelis: General Court upholds opposition for medicinal product names for use and not for use in oncology (Allen & Overy)

On 16 May 2017, the General Court handed down its decision in Alfa Wasserman SpA (AW) v EUIPO, Pharma Mar intervening (Case T- 85/15).  The decision follows the opposition by Pharma Mar (Pharma), owner of the EU trade mark YONDELIS for pharmaceutical and veterinary products and preparations for use in

2017-05-25T12:54:55+00:00 25 mei 2017|Categories: Intellectuele rechten Pharma & lifesciences|Tags: , |

Curing rules on parallel import of pharmaceuticals? (Simont Braun)

CJEU and Belgian Supreme Court on the interaction between free movement of goods and trademark rights. On November 7, 2016 the Belgian Supreme Court (Cour de cassation – Hof van cassatie) gave judgment in two cases regarding the repackaging of pharmaceuticals, wherein it ruled in favour of the parallel importer with

Protecting and enforcing design rights: Benelux (World Trademark Review)

Benelux design law is governed by the Benelux Convention on Intellectual Property, the current version of which entered into force on October 1 2013. The Community Design Regulation is the second important piece of legislation for design law in the Benelux countries. As both the convention and the Community Design

2017-01-09T11:53:02+00:00 9 januari 2017|Categories: Intellectuele rechten|Tags: , |

Repackaging: when is it allowed? (Lydian)

On 10 November 2016, the European Union Court of Justice (ECJ) rendered a judgment regarding the "need of repackaging" of pharmaceuticals and the reaffixing of the trade mark by the parallel importer within the European Economic Area (EEA), which includes Norway. A lot of issues have been raised in the field